Showing results (31-40 of 40) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Journal for Immunotherapy of Cancer|August 17, 2022
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trialKarim Fizazi, Margitta Retz, Daniel P Petrylak, et al.JCO Global Oncology|April 15, 2021
Consensus for Treatment of Metastatic Castration-Sensitive Prostate Cancer: Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC)Fernando Cotait Maluf, Felipe Moraes Toledo Pereira, Pedro Luiz Serrano Uson, et al.European Journal of Cancer (Oxford, England : 1990)|September 23, 2025
177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 studyPhilipp Mandel, Daniel Groener, Giulia Follacchio, et al.Clinical Genitourinary Cancer|August 24, 2024
The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American PopulationVinicius Carrera Souza, Fernando Sabino Marques Monteiro, Fernando Cotait Maluf, et al.Journal of Cancer Research and Clinical Oncology|May 16, 2020
Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG)Andrey Soares, Fernando Sabino Marques Monteiro, Fernando Cotait Maluf, et al.Therapeutic Advances in Urology|September 17, 2019
Renal cell cancer treatment: an expert panel recommendation from the Latin American cooperative group-genitourinary and the Latin American renal cancer group: focus on surgeryStênio de Cássio Zequi, Walter Henriques da Costa, Fernando Korkes, et al.Journal of Cancer Research and Clinical Oncology|April 9, 2024
Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus updateAndrey Soares, Fernando Sabino Marques Monteiro, Karine Martins da Trindade, et al.Cancer Immunology, Immunotherapy : CII|September 7, 2023
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective studyOndřej Fiala, Sebastiano Buti, Hideki Takeshita, et al.Cancer Immunology, Immunotherapy : CII|April 18, 2024
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 studyFrancesco Massari, Matteo Santoni, Hideki Takeshita, et al.European Urology|October 11, 2024
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)Silke Gillessen, Fabio Turco, Ian D Davis, et al.Pageof 4